Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 15;10(3):154. doi: 10.1038/s41419-019-1331-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a EGFR-AS1 expression between tumors >4 cm (n = 119) and tumors ≤4 cm (n = 85) in RCC samples analyzed using qRT-PCR. P < 0.001 by the Mann–Whitney U test. b EGFR-AS1 expression between RCC samples with tumor metastasis (n = 31) and without tumor metastasis (n = 173) analyzed using qRT-PCR. P < 0.01 by the Mann–Whitney U test. c EGFR-AS1 expression between Fuhrman III/IV grade (n = 52) and Fuhrman I/II grade (n = 152) RCC samples analyzed using qRT-PCR. P < 0.05 by the Mann–Whitney U test. d, e Kaplan–Meier analysis of the overall survival (d, P = 0.0075) or recurrence-free survival rate (e, P = 0.0126) of RCC patients with high or low EGFR-AS1 expression. f, g Kaplan–Meier analysis of the overall survival (f, P = 0.029) or recurrence-free survival rate (g, P = 0.013) of RCC patients with high or low EGFR expression. h, i The Pearson correlation analysis of the transcription level of EGFR-AS1 and EGFR in our data (h, n = 80, P = 0.038) and TCGA database(i, P = 0.019). j, k Kaplan–Meier analysis of the overall survival (EGFR-AS1^high&EGFR^high vs EGFR-AS1^high/EGFR^high and EGFR-AS1^low&EGFR^low, P < 0.001) or recurrence-free survival rate(P = 0.002) of RCC patients with high or low EGFR-AS1 and high or low EGFR